North American Biologicals Acquires Pharmaceutical Product for Hepatitis from Abbott Laboratories

OCT 14 '92 08:26 PETER FEINSTEIN INC.

FP.:3

NABI product acquisition
Page 2
H-BIG~ (Hepatitis B immune globulin) is an FDA-licensed product currently
used to provide passive immunity from exposure to Hepatitis B. H-BIG has
been marketed by Abbott for prophylactic use for adults and children exposed
to the virus, and for infants born to Hepatitis B positive mothers. It is often
used in conjunction with Hepatitis B vaccine in order to provide the patient
with both immediate and long-term immunity. The product currently has
sales of approximately $5 million per year. NABI believes that sales can be
significantly increased through additional medical indications and enhanced
international marketing efforts.
HIVIG"M (HIV immune globulin) is intended as a means of providing passivc
immunity to unborn infants or neonates whose mothers are HIV positive.
NABI's right to acquire HIVIG from Abbott is subject to Abbott's receiving
satisfactory immunity from civil lawsuits for clinical and commercial uses of
HIVIG.
Abbott will receive royalties from NABI based upon sales of the acquired
products, Abbott has also agreed to various standstill measures, including
agreements not to acquire additional NABI shares without NABI Board
approval and to vote its NABI shares on most matters in the same proportion
as other NABI shareholders.
North American Biologicals, Inc., headquartered in Miami, Florida, is the
world's largest independent provider of human blood plasma elements to the
health care industry.